Responses
Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
194 Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
